Overview

* Xenetic Q3 revenue rises 67.2% yr/yr, driven by increased royalty revenue

* Net loss for Q3 2025 was $0.5 mln, with increased R&D expenses

* Company secured $3.9 mln from October 2025 offering to extend cash runway

Outlook

* Xenetic advances DNase technology towards Phase 1 clinical trials for solid tumors

* Company plans to invest in pre-clinical efforts and exploratory studies

* Xenetic partners with PeriNess for clinical trials in Israeli medical centers

Result Drivers

* CASH RUNWAY EXTENSION - $3.9 mln secured from October 2025 offering to support research and development

* INCREASED R&D EXPENSES - R&D expenses rose due to manufacturing development and pre-clinical research

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$500,00

Income 0

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)